Search terms
Results 1 - 10 of 47 - ordered by :
Pages: 1 2 3 4 5 ... 5

Results from the SCAAR study, presented at the ESC Congress 2011 today, showed that Percutaneous Coronary Intervention (PCI) with “new generation” Drug Eluting Stents, was associated with ...

Date : 30/08/2011

The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly ...

Date : 03/09/2007

While the investigator-initiated study showed that DAPT (a combination of aspirin and the P2Y12-receptor blocker clopidogrel) does not decrease the rate of major adverse cardiovascular and ...

Date : 31/08/2015

FAME II trial demonstrates the importance of targeting treatment to the right patients A ground breaking international trial, presented yesterday at EuroPCR, has demonstrated for the very first time ...

Date : 16/05/2012

Professor Francois Schiele, Besancon, France, ESC spokesperson and member of the ESC Press Committee, attended the AHA Scientific Sessions held in Chicago, 14-19 November 2014. On the one hand, long ...

Date : 04/01/2014

Within the DAPT trial, a high-risk score (i.e. a score ≥2) selected patients who showed a reduction in MI/stent thrombosis and cardiovascular or cerebrovascular events risk [ (NNT) for benefit for ...

Date : 30/04/2018

Clinical outcome after SES implantation should be regarded as the benchmark for the current and future generation drug-eluting stents.  [...]despite the all-comers trial design, the study ...

Date : 29/08/2011

Chronic coronary syndromes (CCS), of which angina pectoris is an important symptom, have a major societal impact, affecting our patients’ quality of life (QoL) with reduced physical endurance, ...

Date : 22/05/2018

Results of the NIPPON (NoborI dual antiplatelet therapy as aPPrOpriate DuratioN) study, presented at ESC Congress 2016, showed similar rates of “net adverse clinical and cerebrovascular ...

Date : 28/08/2016

Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous ...

Date : 17/05/2016